Experience of Real-Life Use of Dalbavancin as an Off-Label Treatment of Complicated Infectious Diseases in a Tertiary Care Hospital
Resumen: Dalbavancin is a lipoglycopeptide indicated for the treatment of acute bacterial skin and skin structure infections. The aim of this study is to describe the cases in which dalbavancin has been used as an off-label use for the treatment of infections by gram-positive microorganisms. Meth-ods: we carried out a case report series study of all patients treated with dalbavancin as off-label from January 2017 to March 2022. Results: Dalbavancin was administered to seventeen patients. The most frequent diagnosis was osteoarticular infection in 52.94%of patients. The principal isolated microorganism was Staphylococcus epidermidis (47.00%). The posology of dalbavancin was highly variable and the median number of days of treatment was 14 (1–56). At 3 months of treatment only 2 patient died for others reasons and no patient had reinfection. Conclusion: dalbavancin is an an-tibiotic with a novel dosage in infectious diseases of Gram-positive that proven to be high effective because no patient manifested symptoms of reinfection.
Idioma: Inglés
DOI: 10.3390/eca2022-12736
Año: 2022
Publicado en: Medical sciences forum 12, 1 (2022), [4 pp.]
ISSN: 2673-9992

Originalmente disponible en: Texto completo de la revista

Tipo y forma: Congress (Published version)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Ped.Radio.Sal.Pú.)
Exportado de SIDERAL (2022-10-03-16:20:18)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
articulos > articulos-por-area > medicina_preventiva_y_salud_publica



 Notice créée le 2022-07-11, modifiée le 2022-10-04


Versión publicada:
 PDF
Évaluer ce document:

Rate this document:
1
2
3
 
(Pas encore évalué)